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AUC

:   area under the ROC curve

LUAD

:   Lung adenocarcinoma

OS

:   overall survival

ROC

:   receiver operating characteristic

1. INTRODUCTION {#jcla22990-sec-0005}
===============

Lung adenocarcinoma (LUAD or LAC), is a major histological subtype of lung cancer[1](#jcla22990-bib-0001){ref-type="ref"}, [2](#jcla22990-bib-0002){ref-type="ref"} and one of the most common malignant tumors with high incidence and mortality. Lack of typical symptoms and signs in the early stages, patients with LUAD often progress to advanced stages at the time of diagnosis.[3](#jcla22990-bib-0003){ref-type="ref"} As higher stage tumors with higher rates of recurrence, there is a significant proportion of patients with LUAD less than 5‐year survival.[4](#jcla22990-bib-0004){ref-type="ref"}, [5](#jcla22990-bib-0005){ref-type="ref"}, [6](#jcla22990-bib-0006){ref-type="ref"} Therefore, besides histological classification, it is urgently need to develop novel molecular prognostic signature for predicting the risk of disease recurrence and identifying high‐risk subgroup of patients with LUAD who might benefit from adjuvant treatment.

With the development of high‐throughput technology, gene expression profiles have been broadly used to identify more novel biomarkers. Protein‐coding genes (PCGs) are the most common biomarkers and involved in the many key biological processes which can be powerful predictors of survival in patients in different cancers.[7](#jcla22990-bib-0007){ref-type="ref"}, [8](#jcla22990-bib-0008){ref-type="ref"}, [9](#jcla22990-bib-0009){ref-type="ref"}, [10](#jcla22990-bib-0010){ref-type="ref"} Recently, long non‐coding RNAs (lncRNAs) are transcripts \>200 nucleotides with little coding capacity. Long non‐coding RNA (lncRNA) becomes new participant in tumorigenesis due to their various functions in a variety of cancer gene regulatory mechanisms, and has important clinical implications in terms of prognosis.[7](#jcla22990-bib-0007){ref-type="ref"}, [8](#jcla22990-bib-0008){ref-type="ref"}, [9](#jcla22990-bib-0009){ref-type="ref"}, [10](#jcla22990-bib-0010){ref-type="ref"}, [11](#jcla22990-bib-0011){ref-type="ref"}, [12](#jcla22990-bib-0012){ref-type="ref"}, [13](#jcla22990-bib-0013){ref-type="ref"}, [14](#jcla22990-bib-0014){ref-type="ref"} Recent studies have constructed many lncRNA signature[15](#jcla22990-bib-0015){ref-type="ref"}, [16](#jcla22990-bib-0016){ref-type="ref"}, [17](#jcla22990-bib-0017){ref-type="ref"} to predict the prognosis of patients. For instance, a 3‐lncRNA signature can be a new biomarker for the esophageal squamous cell carcinoma prognosis,[18](#jcla22990-bib-0018){ref-type="ref"} an immune‐related 6‐lncRNA signature could improve prognosis prediction of glioblastoma multiforme[19](#jcla22990-bib-0019){ref-type="ref"} and a potential signature of eight long non‐coding RNAs could predict survival in patients with non‐small cell lung cancer.[20](#jcla22990-bib-0020){ref-type="ref"} The advantage of combining PCGs with lncRNAs as prognostic markers is to show the disorder alteration of patients with cancer in greater detail from multiple dimensions.[14](#jcla22990-bib-0014){ref-type="ref"}, [21](#jcla22990-bib-0021){ref-type="ref"}, [22](#jcla22990-bib-0022){ref-type="ref"}, [23](#jcla22990-bib-0023){ref-type="ref"}

Here, we analyzed PCG and lncRNA expression profiles of LUAD from Gene Expression Omnibus and developed a multidimensional transcriptome prognostic signature to predict LUAD survival.

2. MATERIALS AND METHODS {#jcla22990-sec-0006}
========================

2.1. Expression data of LUAD patients {#jcla22990-sec-0007}
-------------------------------------

We acquired the expression data and associated clinical information of patients with LUAD from Gene Expression Omnibus (GEO, <https://www.ncbi.nlm.nih.gov/geo/>). Then, we performed a probe re‐annotation pipeline to get both PCG and lncRNA expression data. Specifically, we downloaded GPL570 probe sequences from Affymetrix (<http://www.affymetrix.com>) website and aligned these probe sequences to the human lncRNA and PCG transcript sequences from GENCODE (<http://www.gencodegenes.org/>), using BLASTn by the followed steps:(a) only retained the probes that matched to one PCG or lncRNA transcript. (b) Removed the probes matched to more than one transcript. (c) Each transcript should be perfectly matched to more than three probes.[24](#jcla22990-bib-0024){ref-type="ref"}

2.2. Construction of a prognostic signature in the training dataset {#jcla22990-sec-0008}
-------------------------------------------------------------------

Survival‐related PCGs and lncRNAs in training dataset were screened out by cox proportional hazards regression analysis (*P* \< .05). In an effort to make the dataset manageable, we used the random survival forests‐variable hunting (RSFVH) algorithm to filter genes until nine PCGs and lncRNAs.[18](#jcla22990-bib-0018){ref-type="ref"} Subsequently, in order to further identify the prognostic genes, multivariable cox regression analysis was performed and a model to estimate prognosis risk was constructed as follows[17](#jcla22990-bib-0017){ref-type="ref"}:$$\text{Risk\ Score} = \sum\limits_{i = 1}^{N}{(\text{ExpVluei} \times \beta_{i})}$$ *N* is the number of prognostic genes, ExpVluei is the expression value of lncRNAs, and *β* ~i~ is the estimated regression coefficient of lncRNAs in the Cox proportional hazards regression analysis. Each patient was assigned 511 risk scores, since nine genes form 2^9^−1 = 511 combinations. We chose prognostic signatures with AUC \> 0.7 and log‐rank *P* \< .05 from all 511 combinations, which were calculated by ROC and Kaplan‐Meier (KM) analysis.

2.3. Statistical analysis and bioinformatics prediction analysis of the prognostic genes function {#jcla22990-sec-0009}
-------------------------------------------------------------------------------------------------

Utilizing the ROC and the timeROC analysis, we compared the predictive efficacy of pathological stage with that of the PCG‐lncRNA signature. Cox proportional hazards regression analysis was performed to test whether the signature was an independent prognostic indicator, with significance defined as *P* \< .05. All analyzes were performed using R program ([www.r-project.org](http://www.r-project.org)), including timeROC, survival, and randomforestSRC (downloaded from Bio‐conductor).

The co‐expressed relationships between PCGs and lncRNAs of the selected signature and all other protein‐coding genes were computed using Pearson\'s test; values with *P* \< .05 and an absolute value of the Pearson coefficient \> 0.3 were selected. We used the R package clusterProfiler to make Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) enrichment.[25](#jcla22990-bib-0025){ref-type="ref"}

3. RESULTS {#jcla22990-sec-0010}
==========

3.1. Patient characteristics and expression profiles {#jcla22990-sec-0011}
----------------------------------------------------

Expression profiles of 417 samples, along with corresponding clinical data of patients diagnosed with LUAD, were downloaded from GSE31210, GSE37745, and GSE30219. The median age of the LUAD patients was 61 years (30‐83 years), and all patients were categorized as stage I, II, III, or IV (Table [1](#jcla22990-tbl-0001){ref-type="table"}). Then, GSE31210 (n = 226) and GSE37745 (n = 106) were served as training sets while GSE30219 (n = 85) dataset was validation set.

###### 

Summary of patient demographics and clinical characteristics

  Characteristic       GSE31210   GSE37745   GSE30219
  -------------------- ---------- ---------- ----------
  Age (y)                                    
  \>61                 122        47         46
  ≤61                  104        59         39
  Sex                                        
  female               121        60         19
  Male                 105        46         66
  Vital status                               
  Living               191        29         40
  Dead                 35         77         45
  Pathological stage                         
  Stage Ⅰ              168        70          
  Stage Ⅱ              58         19          
  Stage Ⅲ                         13          
  Stage Ⅳ                         4           
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3.2. Identification of prognostic genes from the training dataset {#jcla22990-sec-0012}
-----------------------------------------------------------------

Through probe reannotating the Affymetrix Human Genome U133 Plus 2.0 Array, we obtained the lncRNA and PCG expression profiles of the 417 LUAD patients. Then, we selected 1897 PCGs and 529 lncRNAs associated with survival of patients with LUAD via cox proportional hazards regression analysis (*P* \< .05). Seven PCGs and two lncRNAs (ANGPT4, MESD, ZMYM5, MANF, NHLRC2, PLIN5, GNAI3, [AC006128.1](AC006128.1), [AC087521.1](AC087521.1)) with a strong correlation to patient survival were found according to the importance score calculated by random survival forests‐variable hunting (RSFVH) (Figure [1](#jcla22990-fig-0001){ref-type="fig"}A,B).

![Screening steps of the prognostic PCG‐lncRNA signature in the training dataset. Random survival forests‐variable hunting analysis revealed the lowest error rate for the data as a function of trees (A), and the associated scores were used to filter genes (B). The AUC of all 511 signatures was calculated and the first nine AUC are shown in the plot. D, ROC analysis of the selected prognostic PCG‐lncRNA signature(C)](JCLA-33-na-g001){#jcla22990-fig-0001}

3.3. Construction of the prognostic multi‐gene signature in the training dataset {#jcla22990-sec-0013}
--------------------------------------------------------------------------------

The seven PCGs and two lncRNAs could generate 2^9^−1 = 511 signatures, and each signature corresponded to a risk score ($\text{Risk\ Score} = \sum\limits_{i = 1}^{N}{(\text{ExpVluei} \times \beta_{i})}$); detailed in Methods). ROC analyzes were performed on all 511 signatures and compared their AUC. The PCG‐lncRNA combination composed of three PCG (NHLRC2, PLIN5, GNAI3), and one lncRNA ([AC087521.1](AC087521.1)) with the largest AUC (0.76) and minimum number of genes was selected (Figure [1](#jcla22990-fig-0001){ref-type="fig"}C,D, Table [2](#jcla22990-tbl-0002){ref-type="table"}). The risk score equation was calculated as: Risk score = (1.32 × expression value of [AC087521.1](AC087521.1)) + (2.56 × expression value of GNAI3) + (−1.00 × expression value of PLIN5) +  (−1.76 × expression value of NHLRC2). The hazard ratio of the selected signature in the training group was 20.84 (*P* \< .05), indicating that the PCG‐lncRNA is a risk factor of LUAD.

###### 

Characteristics of PCGs and lncRNA in the signature

  Database ID[a](#jcla22990-note-0001){ref-type="fn"}   Gene symbol                Gene name                    Coefficient[b](#jcla22990-note-0002){ref-type="fn"}   *P* [b](#jcla22990-note-0002){ref-type="fn"}   Expression with poor prognosis   Chromosome location
  ----------------------------------------------------- -------------------------- ---------------------------- ----------------------------------------------------- ---------------------------------------------- -------------------------------- --------------------------
  ENSG00000196865                                       NHLRC2                     NHL repeat containing 2      −1.76                                                 .00                                            low                              10:113854661‐113917194:1
  ENSG00000214456                                       PLIN5                      Perilipin 5                  −1.00                                                 .01                                            low                              19:4522531‐4535224:‐1
  ENSG00000065135                                       GNAI3                      G protein subunit alpha i3   2.56                                                  .00                                            high                             1:109548611‐109618321:1
  ENSG00000244953                                       [AC087521.1](AC087521.1)                                1.32                                                  .00                                            high                             11:43943787‐43947206:−1

Ensembl database.

Derived from the univariable Cox regression analysis in the training set.
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3.4. The selected signature for survival prediction in the training and test datasets {#jcla22990-sec-0014}
-------------------------------------------------------------------------------------

In the training dataset, each patient was assigned a risk score by the prognostic model based on the PCG‐lncRNA signature. As the median risk score as a cutoff point, patients from the training dataset were divided into a high‐risk group (n = 113) and a low‐risk group (n = 113).Then Kaplan‐Meier survival analyzes were performed and found patients from the high‐risk group had a significantly lower overall survival rate (OS) than those from the low‐risk group (log‐rank test *P* \< .001; Figure [2](#jcla22990-fig-0002){ref-type="fig"}A). When applied the median risk score to the GSE37745 and GSE30219 sets, patients from the two test sets were also divided into two groups, respectively, namely high‐risk groups(n = 53/42) and low‐risk groups (n = 53/43).Similarly, the survival of patients in the high‐risk groups was significantly shorter than those in the low‐risk groups (GSE37745 median 2.78, 95% CI: 1.46‐4.01 vs 5.94 years, 95% CI: 4.11‐7.22, log‐rank test *P* \< .001, Figure [2](#jcla22990-fig-0002){ref-type="fig"}B; GSE30219 median 4.58, 95% CI: 2.33‐12.5 vs 16.25 years, 95% CI: 8.58‐16.73, log‐rank test *P* = .0063, Figure [2](#jcla22990-fig-0002){ref-type="fig"}C).

![The PCG‐lncRNA signature predicted overall survival of patients with LUAD. Kaplan‐Meier survival curves classified patients into high‐ and low‐risk groups by the PCG‐lncRNA signature in the GSE31210 (A) and GSE37745, GSE30219 (B, C) datasets. *P* values were calculated by log‐rank test](JCLA-33-na-g002){#jcla22990-fig-0002}

According to the gene expression, risk score distribution and survival status of patients, Figure [3](#jcla22990-fig-0003){ref-type="fig"} illustrated the association of the gene expression with the survival. In the training dataset (Figure [3](#jcla22990-fig-0003){ref-type="fig"}A), GSE37745 (Figure [3](#jcla22990-fig-0003){ref-type="fig"}B), and GSE30219 (Figure [3](#jcla22990-fig-0003){ref-type="fig"}C), patients with high expression of NHLRC2 and PLIN5 or low‐risk scores had a higher probability of survival, and patients with high‐risk scores or high‐expressed [AC087521.1](AC087521.1) and GNAI3 had shorter survival time.

![Risk score distribution, survival status, and gene expression patterns of patients with LUAD in the GSE31210 (A) and GSE37745 (B), GSE30219 (C) dataset](JCLA-33-na-g003){#jcla22990-fig-0003}

3.5. The selected signature is an independent prognostic indicator {#jcla22990-sec-0015}
------------------------------------------------------------------

To better understand the clinical significance of the PCG‐lncRNA signature in patients with LUAD, we also examined the association of the PCG‐lncRNA signature with a series of clinical parameters in the dataset. There was no association between the PCG‐lncRNA signature and clinicopathological parameters in the training and test datasets, except pathological stage in the training set (Chi‐square test, *P* \< .05, Table [3](#jcla22990-tbl-0003){ref-type="table"}). Therefore, we performed a cox proportional hazards regression analysis to assess predictive independence of the PCG‐lncRNA signature. The *P* values of the prognostic signature in the cox proportional hazards regression analysis from the training datasets were \<.05, which showed that the PCG‐lncRNA signature risk score was an independent prognostic indicator for patients with LUAD and was not affected by clinical features including sex, age, and pathologic stage (high‐risk group vs low‐risk group, HR = 15.79, 95% CI 3.70‐67.33, *P* \< .001, n = 226, Table [4](#jcla22990-tbl-0004){ref-type="table"}). The independence of the PCG‐lncRNA signature was validated in two test sets (high‐risk group vs low‐risk group, HR = 2.27, 95% CI 1.42‐3.63, *P* \< .001, n = 106/HR = 2.39, 95% CI 1.28‐4.48, *P* = .01; Table [4](#jcla22990-tbl-0004){ref-type="table"}).

###### 

Association of the PCG‐lncRNA signature with clinicopathological characteristics in patients with LUAD

  Variables            Train group   *P*   Test group 1   *P*   Test group 2   *P*              
  -------------------- ------------- ----- -------------- ----- -------------- ------ ---- ---- -----
  Age                                      .69                                 .43              1
  ≤61                  63            59                   26    21                    23   23    
  \>61                 50            54                   27    32                    20   19    
  Sex                                      .02                                 1.00             .27
  Female               70            51                   30    30                    7    12    
  Male                 43            62                   23    23                    36   30    
  Pathological stage                       .00                                 .49               
  Stage Ⅰ              100           68                   37    33                               
  Stage Ⅱ              13            45                   8     11                               
  Stage Ⅲ                                                 5     8                                
  Stage Ⅳ                                                 3     1                                

Low risk ≤ median of risk score, high risk \> median of risk score; The Chi‐squared test; *P* value \< .05 was considered significant.
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###### 

Univariable and multivariable Cox regression analysis of the signature with LUAD survival

  Variables                   Univariable analysis    Multivariable analysis                                             
  --------------------------- ----------------------- ------------------------ ------ ------- ----- ------ ------ ------ -----
  GSE31210 dataset(n = 226)                                                                                              
  Age                         \>61 vs ≤61             1.43                     0.73   2.78    .29   1.32          2.10   .23
  Sex                         Male vs Female          1.52                     0.78   2.96    .22   1.26   0.80   1.97   .32
  Pathological stage          II vs I,                4.23                     2.17   8.24    .00   1.32   1.03   1.68   .03
  PCG‐signature               High risk vs low risk   20.84                    5.00   86.93   .00   2.32   1.46   3.69   .00
  GSE37745 set (n = 106)                                                                                                 
  Age                         \>61 vs ≤61             1.34                     0.68   2.61    .40   1.14   0.71   1.84   .58
  Sex                         Male vs Female          1.11                     0.57   2.19    .75   1.43   0.90   2.26   .13
  Pathological stage          III, IV vs I, II        2.30                     1.16   4.55    .02   1.27   0.99   1.64   .06
  PCG‐signature               High risk vs low risk   15.79                    3.70   67.33   .00   2.27   1.42   3.63   .00
  GSE30219 set (n = 85)                                                                                                  
  Age                         \>61 vs ≤61             1.88                     1.03   3.41    .04   1.85   1.01   3.37   .04
  Sex                         Male vs Female          1.02                     0.49   2.13    .95   1.37   0.65   2.90   .41
  PCG‐signature               High risk vs low risk   2.29                     1.24   4.22    .01   2.39   1.28   4.48   .01

John Wiley & Sons, Ltd

3.6. Comparison of the survival prediction efficiency of the PCG‐lncRNA signature with pathologic stage {#jcla22990-sec-0016}
-------------------------------------------------------------------------------------------------------

Since GSE30219 without pathological stage information, we performed ROC analysis in two datasets (GSE31210/GSE37745, n = 226/106) to compare the survival prediction efficiency of pathological stage and the PCG‐lncRNA signature. The AUC of the PCG‐lncRNA signature was bigger than AUC of the pathological stage (Signature‐AUC = 0.76/0.68 vs Stage‐AUC = 0.65/0.62, Figure [4](#jcla22990-fig-0004){ref-type="fig"}A,B). The high predictive efficacy demonstrated the PCG‐lncRNA signature has important clinical significance.

![Comparison of the survival predictive power of the signature and that of pathological stage by ROC analysis in the GSE31210, and GSE37745 datasets (A, B). Survival predictive power of the signature (C, E) and pathological stage (D, F) at 3, 5, 8 years in the GSE31210 and GSE37745 dataset was analyzed by ROC analysis](JCLA-33-na-g004){#jcla22990-fig-0004}

TimeROC analysis was performed in the training dataset (n = 226), and we found that the AUC of the PCG‐lncRNA signature was greater than the AUC of the pathological stage (Signature‐AUC = 0.73/0.78/0.84 at 3/5/8 years vs Stage‐AUC = 0.75/0.64/0.73 at 3/5/8 years, Figure [4](#jcla22990-fig-0004){ref-type="fig"}C,D). We also observed the same results in the GSE37745 dataset (Signature‐AUC = 0.64/0.63/0.62 at 3/5/8 years vs Stage‐AUC = 0.58/0.55/0.57 at 3/5/8 years, Figure [4](#jcla22990-fig-0004){ref-type="fig"}E,F).

3.7. Gene oncology and KEGG pathway enrichment analysis {#jcla22990-sec-0017}
-------------------------------------------------------

To characterize the molecular function of lncRNAs and PCGs in the PCG‐lncRNA signature, firstly, we screened out their co‐expressed protein‐coding genes from the GSE31210 and GSE37745 datasets and computed pearson correlation coefficients. Of these, 2654 protein‐coding genes were highly correlated with at least one of the selected genes, in the GSE31210 and GSE37745 datasets (Pearson correlation coefficient \> 0.3/\<−0.3, *P* \< .05). Gene oncology and KEGG pathway enrichment analysis of the 2654 protein‐coding genes demonstrated that they were enriched in 38 gene oncology terms (GO terms) and KEGG pathways, including ncRNA transcription, response to insulin and snRNA transcription by RNA polymerase II checkpoint (*P* \< .05, Figure [5](#jcla22990-fig-0005){ref-type="fig"}).

![Gene oncology and KEGG pathway enrichment analysis of the PCGs and lncRNAs in the signature](JCLA-33-na-g005){#jcla22990-fig-0005}

4. DISCUSSION {#jcla22990-sec-0018}
=============

In recent years, the development of high‐tech sequencing makes novel PCGs or lncRNA signatures become a hot topic in cancer prognostic research. Although pathological stage is a commonly used prognostic method in clinical practice, its accuracy and effectiveness are insufficient for patients with LUAD.

In this study, we examined the clinical information and gene expression data of GSE31210 and identified a PCG‐lncRNA signature which could predict the survival of patients with LUAD. The PCG‐lncRNA signature was closely correlated with the overall survival rate of patients with LUAD in two test sets, indicating it could be a reliable indicator of survival. Cox proportional hazards regression analysis was performed to assess the independence of the selected PCG‐lncRNA signature in predicting the overall survival of patients with LUAD in the training and the test dataset. The PCG‐lncRNA signature maintained its correlation with the overall survival rate when coupled with age, gender, and pathological stage as covariables. This suggests that the predictive power of the PCG‐lncRNA signature is independent of these other clinical features. ROC analysis co‐founds that the prognostic ability of the signature is stronger than pathological stage, indicating that the signature could be an additional biomarker of the pathological stage.

We found high expression of GNAI3, [AC087521.1](AC087521.1) was associated with a short survival time (HR \> 1, *P* \< .05) and NHLRC2, PLIN5 was associated with a long survival time (HR \< 1, *P* \< .05). There was a study demonstrated that expression of GNAI3 shared a tight relationship with the prognosis of patients with hepatocellular carcinoma,[26](#jcla22990-bib-0026){ref-type="ref"} but few research reported the function of [AC087521.1](AC087521.1), NHLRC2, and PLIN5 in cancer. While our study explored the function of these four prognostic genes by bioinformatic analysis, the biological role of them in LUAD tumorigenesis is still not clear and warrants further study. Additionally, experimental studies on these genes are needed to deepen understanding of the prognostic mechanisms behind the PCG and lncRNA, and enhance our understanding of their functional roles. In 417 LUAD samples, we confirmed that the signature is an effective marker for LUAD patients\' prognosis, but this conclusion that selected PCG‐lncRNA signature may complement the pathological stage in a clinical setting would benefit from additional study.

In conclusion, using bioinformatics analysis, we identified a PCG‐lncRNA signature composed of [AC087521.1](AC087521.1), GNAI3, NHLRC2, and PLIN5 that accurately predicted the overall survival of patients with LUAD based on three LUAD independent datasets. However, additional large‐scale study is needed before the current results can be applied in clinical settings.
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